Back to the basics: The need for an etiological classification of chronic heart failure

Filippos Triposkiadis1, Andrew Xanthopoulos2, Stavros G Drakos3

  • 1School of Medicine, European University Cyprus, Nicosia 2404, Cyprus; Department of Cardiology, University Hospital of Larissa, Larissa 41110, Greece.

PubMed

Insights

The traditional left ventricular ejection fraction (LVEF) classification for heart failure (HF) is outdated. New evidence suggests an etiological approach is better for guiding HF treatment and precision medicine.

Area of Science:

  • Cardiology
  • Heart Failure Research
  • Clinical Medicine

Background:

  • The left ventricular ejection fraction (LVEF) has long been central to heart failure (HF) classification and management.
  • This classification has been favored because it identifies patient groups benefiting from specific treatments.

Purpose of the Study:

  • To review evidence challenging the utility of LVEF in HF classification.
  • To advocate for a shift towards contemporary concepts in guiding chronic HF treatment.

Main Methods:

  • Review of current evidence regarding LVEF in HF classification and treatment guidance.
  • Analysis of the limitations of LVEF in guiding medical, device, and mechanical circulatory support therapies.
  • Proposal of an alternative etiologic HF classification.

Main Results:

  • The rationale for LVEF-based HF classification has weakened, as neurohormonal inhibitors benefit most HF patients irrespective of LVEF.
  • LVEF is a poor predictor for device therapies like implantable cardioverter-defibrillators and cardiac resynchronization therapy.
  • LVEF is an inadequate surrogate for LV size in LV assist device implantation.

Conclusions:

  • The reliance on LVEF for HF classification and treatment guidance is increasingly untenable.
  • A transition to etiologic HF classification, based on epidemiological data, is proposed.
  • This new classification will support higher-resolution phenotyping for precision medicine in HF.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
180
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.8K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431